Hemodynamics and Extravascular Lung Water in Acute Lung Injury

Bio2RDF uri

Hemodynamics and Extravascular Lung Water in Acute Lung Injury

http://bio2rdf.org/clinicaltrials:NCT00624650

Bio2RDF identifier

NCT00624650

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00624650

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00624650

acronym [clinicaltrials_vocabulary:acronym]

HEAL

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of this stu ...... ry to see if this is helpful.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Hemodynamics and Extravascular Lung Water in Acute Lung Injury

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

The primary efficacy variable will be the total reduction in measured lung water The first seven days of treatment [clinicaltrials_resource:d1684cd5e6cdc8b731478851f3683295]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

The primary efficacy variable will be the total reduction in measured lung water The first seven days of treatment [clinicaltrials_resource:00a468367ce02fdacc91233497b9284c]

The primary efficacy variable will be the total reduction in measured lung water The first seven days of treatment [clinicaltrials_resource:129025af8dd02db67199c05972dc0d1f]

The primary efficacy variable will be the total reduction in measured lung water The first seven days of treatment [clinicaltrials_resource:1a0e963c857af062d531701576021fff]

The primary efficacy variable will be the total reduction in measured lung water The first seven days of treatment [clinicaltrials_resource:3d5c1746513ba32a7c1323d3bcbe29e5]

The primary efficacy variable will be the total reduction in measured lung water The first seven days of treatment [clinicaltrials_resource:509d7b7bc4cbeffc799f6423ab9f5187]

The primary efficacy variable will be the total reduction in measured lung water The first seven days of treatment [clinicaltrials_resource:7eb05f26fb359af2c17ee251d4fce3bb]

The primary efficacy variable will be the total reduction in measured lung water The first seven days of treatment [clinicaltrials_resource:88eda3ebc20c280008ff88a4f98fdea5]

The primary efficacy variable will be the total reduction in measured lung water The first seven days of treatment [clinicaltrials_resource:8cb918f74d9f01532ad2648d285ac42f]

The primary efficacy variable will be the total reduction in measured lung water The first seven days of treatment [clinicaltrials_resource:907c26186d41e2198b5c736362e48d54]

The primary efficacy variable will be the total reduction in measured lung water The first seven days of treatment [clinicaltrials_resource:91076ab3401097b71e8eecb9a9210224]

collaborator [clinicaltrials_vocabulary:collaborator]

Oregon Health and Science University [clinicaltrials_resource:6801742e9022d24820816a39d22aa9c2]

completion date [clinicaltrials_vocabulary:completion-date]

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Acute Lung Injury [clinicaltrials_resource:35169134005f5c2102ace651e95786fe]

condition browse [clinicaltrials_vocabulary:condition-browse]

Lung Injury [clinicaltrials_resource:007ee4777eba672a7514b938348289d1]

Acute Lung Injury [clinicaltrials_resource:35169134005f5c2102ace651e95786fe]

Respiratory Distress Syndrome, Adult [clinicaltrials_resource:40d44971cf0bf4ff8b1e70a662bb479e]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Lung Injury [clinicaltrials_resource:007ee4777eba672a7514b938348289d1]

Acute Lung Injury [clinicaltrials_resource:35169134005f5c2102ace651e95786fe]

Respiratory Distress Syndrome, Adult [clinicaltrials_resource:40d44971cf0bf4ff8b1e70a662bb479e]

country [clinicaltrials_vocabulary:country]

United States [clinicaltrials_resource:f253efe302d32ab264a76e0ce65be769]

detailed description [clinicaltrials_vocabulary:detailed-description]

The objective of this s ...... VLW towards the normal range.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00624650 [clinicaltrials_resource:6a8d7c6fe72489ee70cb3a8f99917a56]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2008-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Dialysis [clinicaltrials_resource:1c72145983b2b4ef2897a6ee31927433]

Dobutamine [clinicaltrials_resource:2a0bdb13297746969a526adf16677c63]

Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine) [clinicaltrials_resource:52214b250ba9f3e573e227100fd63930]

Fluid Bolus (crystalloid or albumin) [clinicaltrials_resource:5dd2d11a750a181ce3b2ad0ece2cd8c6]

Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine) [clinicaltrials_resource:8947efb6a919c4cc8bcab697889a6eae]

Diuresis (furosemide) part I [clinicaltrials_resource:a2bb8a546a096283f22921b7a9fabd9e]

Concentrate all drips and nutrition [clinicaltrials_resource:a8eccd95631a9e16bbe2d4b64ceb42b9]

Dobutamine [clinicaltrials_resource:b88feb1e6aa7b3d564f659a12a1420db]

Fluid Bolus (crystalloid or albumin) [clinicaltrials_resource:beecd06057e5a9bbb70e7f97d5c18e3f]

Diuresis (furosemide) part II [clinicaltrials_resource:c9840feda088ca1940bc5c643a0c18f1]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Furosemide [clinicaltrials_resource:015b96f02895ccd4fd5798fba0a9330a]

Phenylephrine [clinicaltrials_resource:1960a6a9da9eaedbfcd283954ff7a6f0]

Epinephryl borate [clinicaltrials_resource:2a3717b6ad51985af344b7b8ee9bbc4a]

Dobutamine [clinicaltrials_resource:311eb6b1c1c8c89c8826d8673cc4d623]

Epinephrine [clinicaltrials_resource:39e38c19caa599eb64852fea6166e9fd]

Vasopressins [clinicaltrials_resource:3d5c79a318b866f54050816e9f3d23f0]

Vasoconstrictor Agents [clinicaltrials_resource:86eb53a25a8aec708f17e635254b4071]

Arginine Vasopressin [clinicaltrials_resource:92cf7011c8bb7fae226209ce173557d8]

Racepinephrine [clinicaltrials_resource:b530ca7b8c1c38da5e86875f2cc4e68e]

Oxymetazoline [clinicaltrials_resource:d0ba34dd680d64be56df534ec7ab4189]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

Acute Lung Injury

http://www.w3.org/2001/XMLSchema#string

Acute Respiratory Distress Syndrome

http://www.w3.org/2001/XMLSchema#string

Extravascular Lung Water

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2011-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Oregon Health and Science University [clinicaltrials_resource:6801742e9022d24820816a39d22aa9c2]

location [clinicaltrials_vocabulary:location]

Kaiser Permanente Sunnyside [clinicaltrials_resource:b2cc08d452cccb5c083c4187e24f079b]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00624650

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Hemodynamics and Extravascular ...... Treatment of Acute Lung Injury

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

IRB00003491

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Charles Phillips, M.D. [clinicaltrials_resource:b4b08b68bcbc5064bc4e07dbdf4f4f83]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Institutional Review Board [clinicaltrials_resource:b5a2933cbbd357d5860e15ecc488e5c1]

phase [clinicaltrials_vocabulary:phase]

Phase 2 [clinicaltrials_resource:56e0338b27a2d68f77402c88327b3f8d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reference [clinicaltrials_vocabulary:reference]

10068526 [pubmed:10068526]

10619802 [pubmed:10619802]

10622750 [pubmed:10622750]

10648320 [pubmed:10648320]

10793162 [pubmed:10793162]

10793167 [pubmed:10793167]

10903232 [pubmed:10903232]

10988202 [pubmed:10988202]

11243970 [pubmed:11243970]

11255595 [pubmed:11255595]

responsible party [clinicaltrials_vocabulary:responsible-party]

Charles Phillips, M.D., Associate Professor of Medicine, Oregon Health and Science University [clinicaltrials_resource:8610a154b7b51a95037cb324b0b31bd8]

secondary id [clinicaltrials_vocabulary:secondary-id]

IRB #e2978

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Oregon Health and Science University [clinicaltrials_resource:6801742e9022d24820816a39d22aa9c2]

start date [clinicaltrials_vocabulary:start-date]

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00624650 study design [clinicaltrials_resource:e5e8218c8796402f8567588bdbf2d73f]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00624650

verification date [clinicaltrials_vocabulary:verification-date]

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00624650

http://www.w3.org/2001/XMLSchema#string

title

Hemodynamics and Extravascular Lung Water in Acute Lung Injury

@en